Clinical MAPPs: a personalized healthcare-driven assay for the direct identification of potential T cell epitopes in...

The development of anti-drug antibodies (ADAs) in response to therapeutic monoclonal antibody (mAb) treatments can undermine their efficacy and safety. A key player in this immunogenicity is the presentation of mAb-derived peptides by dendritic cells, which activates CD4+ T-helper cells. Traditionally, the MHC class II-associated peptide proteomics (MAPPs) assay is used preclinically to identify these peptides presented by monocyte-derived dendritic cells (moDCs). Here, we are introducing "clinical MAPPs", an optimized, miniaturized version of the assay tailored for clinical use. Designed to work with cryopreserved peripheral blood mononuclear cells from low blood volumes (10 mL), clinical MAPPs offers a groundbreaking approach. Our proof-of-concept on patient material shows that clinical MAPPs enables personalized characterization of MHC-II receptor-associated antibody-derived peptides before mAb treatment. This innovative assay promises to be a critical tool for clinical immunogenicity risk assessments, enhancing personalized healthcare and ensuring safer, more effective treatments.